

Sexually Transmitted Infections and HIV

Amanda Allmacher, DNP, AAHIVS

Detroit Public Health STD Clinic



AIDS Research and Education Center
MATEC Michigan


Disclaimer



This presentation is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$3,139,511.00 with zero percent financed with nongovernmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.

BACKGROUND

- Sexually transmitted infections and HIV are some of the most critical health challenges facing the nation today
 - 20 million persons in the United States acquire a new STI each year
 - STIs affect people:
 - Of all ages
 - From all economic backgrounds
 - Some groups carry a greater burden of disease than others
- Many STIs are curable; all are treatable
- Many STIs are asymptomatic
 - People can and do transmit without knowing they have an STI
- STIs and BV can increase the risk of HIV acquisition by damaging the mucosal barrier and increasing pro-inflammatory cytokines, increasing the availability of HIV target cells



MOST AT RISK POPULATIONS

Gay, Bisexual & Other Men who Have Sex with Men

- ▶ 54% of syphilis cases occurred within this population in 2018
- ▶ 42% of men who have sex with men who have syphilis also have HIV in 2018
- ▶ Data suggest men who have sex with men are disproportionately affected by gonorrhea

Youth

- ▶ 15-24 year-olds make up about 25% of the sexually active population but account for half of the 20 million new STIs that occur in the United States each year
- ▶ Young women (ages 15-24) account for 44% of reported chlamydia cases

Pregnant Women & Infants

- ▶ Syphilis rates among women increased 173% from 2014-2018
- ▶ Significant increases in congenital syphilis mirror increases in syphilis among women
- ▶ 94 infants died in 2018 due to syphilis-related complication, an avoidable tragedy

STIs ON THE RISE

Sexually Transmitted Diseases compromise Americans' health and cost millions of dollars in healthcare

Annual medical cost for treatment of



SYPHILIS \$48M



GONORRHEA \$198M



CHLAMYDIA \$632M

STDs Have Surged, Reaching an All-Time High

Gonorrhea has increased 63% since 2014:

- ▶ 580,000 cases of gonorrhea reported in 2018, the highest number since 1991
- ▶ There is now only 1 recommended regimen of antibiotics to treat gonorrhea



Syphilis has increased 71% since 2014, with more than 115,000 cases in 2018.

Chlamydia has increased 19% since 2014, with more than 1.7 million cases in 2018.

MICHIGAN STATISTICS

- The MDHHS Sexually Transmitted Infections (STIs) statistics website reports statistics for three reportable diseases: chlamydia, gonorrhea, and syphilis
 - Syphilis is grouped by all syphilis, or as primary and secondary syphilis (most transmissible stages)
- Published information for these diseases is presently available for the years 1997 through 2019
 - This information is divided into trend tables and yearly tables by gender, age, counties and health districts

MICHIGAN STATISTICS CONT.

- Chlamydia is the most commonly reported STI in Michigan, at a rate of 504 per 100,000 in 2019
 - Down from 512 per 100,000 population in 2018
- Gonorrhea is the second most commonly reported STI in Michigan, with 182 cases per 100,000 people in 2019
 - Up from rate 154 per 100,000 in 2017
- Primary and secondary infections due to syphilis occurred at rate of 6.9 per 100,000 in 2019
 - Up from rate of 4.8 per 100,000 population in 2017

HIV: MICHIGAN STATISTICS

- Young (ages 15-29), black, men who have sex with men are highest risk
 - Make up 0.1% of the State's population but in 2018 this group comprised 22% of new HIV diagnoses
- HIV epidemic disproportionately affects the City of Detroit, with a 2018 prevalence rate of 713. per 100,000 residents
 - A rate 3.5x higher than the next highest jurisdiction – the rest of Wayne County
- STI/HIV Syndemic
 - In 2018, 36% of people living with HIV diagnosed with an STI did not have a suppressed virus

SEXUALLY TRANSMITTED INFECTIONS: DISPARITIES

Disproportionately affect Black Michiganders

Chlamydia cases disproportionately affect women, syphilis in men more common

Sexually Transmitted Cases By Race, Gender and Disease, Michigan Residents, 2019

All Cases

Race or Hispanic Ancestry	Chlamydia		Gonorrhea		Primary & Secondary Syphilis		All Syphilis	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Total	50,374	100.0	18,264	100.0	685	100.0	1,900	100.0
White	14,789	29.4	3,679	20.1	246	35.9	644	33.9
Black	20,015	39.7	10,395	56.9	371	54.2	1,063	55.9
American Indian	176	0.3	53	0.3	4	0.6	9	0.5
Asian and Pacific Islander	33	0.1	11	0.1	3	0.4	18	0.9
Other Race	15	-	2	-	7	1.0	24	1.3
Hispanic	2,066	4.1	567	3.1	46	6.7	128	6.7
Not Reported	10,562	21.0	2,755	15.1	4	0.6	14	0.7


For example, 55% of all syphilis cases and 57% of all gonorrhea cases in 2019, despite being only 14% of population

Rate of Chlamydia, Gonorrhea and Syphilis Cases by Sex Michigan Residents, 2001-2019

Gender	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Rate of Chlamydia Cases (Rates by Age ▶)																			
Total	311.2	322.2	324.6	410.2	385.3	380.0	412.9	468.0	487.4	510.6	506.9	492.9	455.5	452.5	480.7	477.6	511.9	512.8	504.4
Male	133.4	145.3	135.3	174.6	172.7	182.9	194.2	229.9	251.4	271.0	272.9	273.4	262.6	266.3	295.8	304.6	338.5	346.9	350.1
Female	482.4	492.7	507.1	637.5	588.2	568.1	620.3	693.5	711.1	738.9	730.2	702.7	640.8	631.1	658.6	644.6	678.9	673.1	653.7
Rate of Gonorrhea Cases (Rates by Age ▶)																			
Total	171.4	147.5	139.1	172.8	175.9	165.3	173.2	180.0	156.9	140.9	132.3	129.2	106.6	97.5	107.0	129.6	154.7	169.3	182.9
Male	164.5	138.3	124.5	157.2	151.3	143.7	145.4	146.7	129.3	118.5	110.3	112.6	96.5	93.1	108.4	132.3	162.2	179.2	194.2
Female	178.0	156.3	153.1	187.8	198.7	185.5	199.0	209.2	180.2	162.1	153.2	144.9	116.3	101.7	105.4	126.9	147.2	159.6	171.8
Rate of Primary & Secondary Syphilis Cases (Rates by Age ▶)																			
Total	4.3	4.9	2.5	1.9	1.0	1.2	1.4	2.2	2.3	2.3	2.8	3.0	5.0	4.3	4.0	3.8	4.8	6.5	6.9
Male	5.4	6.0	3.2	2.7	1.7	2.0	2.2	3.2	3.8	4.2	5.1	5.5	9.6	8.2	7.5	7.0	9.1	11.9	12.0
Female	3.2	3.8	1.8	1.2	.4	.5	.6	1.2	.8	.4	.5	.6	.6	.6	.7	.6	.7	1.4	1.9
Rate of All Syphilis Cases (Rates by Age ▶)																			
Total	11.5	11.7	8.5	8.1	4.9	4.0	5.1	5.9	6.0	6.1	7.5	7.7	10.9	11.3	11.0	11.6	13.1	17.1	19.0
Male	12.9	13.1	9.4	9.5	6.4	4.9	6.7	7.6	8.9	9.6	11.9	12.8	18.6	18.5	18.2	20.1	22.6	29.4	31.0
Female	10.2	10.4	7.7	6.8	3.4	3.1	3.5	4.3	3.2	2.8	3.3	2.7	3.5	4.3	4.1	3.4	3.9	5.2	7.4

MICHIGAN STI TRENDS

- Between 2013 and 2015, Michigan saw a slow decline in reported cases of chlamydia, gonorrhea and syphilis
 - Recent health department reports reveal cases of all three STDs rose in 2016-2018
 - Chlamydia: 8%
 - Gonorrhea: 20%
 - Syphilis: 28%
 - A majority of the increases occurred among adolescents, Black men and women, and men who have sex with men



STI DATA QUALITY

- The completeness of data presented in MDHHS reports and tables is affected by two factors that relate to data accuracy and comparability
 - Data is complete only in so far as:
 - Individuals have sought testing
 - Records of such testing have been reported to MDHHS
- Counties and local health departments where greater funds are available for testing may show greater rates of reportable STIs simply because they have been able to test more people
 - It is likely that the number of cases reported statewide under-represents the incidence of sexually transmitted diseases in Michigan
 - For chlamydia and gonorrhea, this under-representation may be substantial
 - Impact of COVID-19 on testing and reporting, yet to be known

EXPEDITED PARTNER THERAPY



Bureau of Local Health & Administrative Services
Division of Health, Wellness and Disease Control
Sexually Transmitted Disease (STD) Section

Guidance for Health Care Providers

Expedited Partner Therapy (EPT) For Chlamydia and Gonorrhea

Public Act 525 of 2014 (MCL 333.5110) authorized the use of expedited partner therapy (EPT) for certain sexually transmitted diseases as designated by the state health department. In January 2015, the department designated chlamydia and gonorrhea as diseases for which the use of EPT is appropriate. This document provides health care providers with guidance for using EPT.

- Expedited Partner Therapy (EPT) is an alternative strategy to assure that sexual partners of patients diagnosed with uncomplicated *Chlamydia trachomatis*, *Neisseria gonorrhoeae* or *Trichomoniasis vaginalis* are treated
 - Due to the high risk of repeat infection from exposure to untreated partners, patients diagnosed with CT, GC or TV cannot be considered adequately treated until all partners have been treated
- Michigan's Public Health Code¹ was amended in 2014, authorizing the use of EPT, which enables clinicians to provide patients with medication or a prescription to deliver to their sex partner(s) without a medical evaluation or clinical assessment of those partners

Expedited
Partner Therapy

SEXUALLY TRANSMITTED INFECTIONS COVERED IN THIS PRESENTATION

- Bacterial vaginosis
- Trichomoniasis
- Chlamydia
- Gonorrhea
- Genital herpes
- Human papilloma virus
- Syphilis




BACTERIAL VAGINOSIS

- The most common vaginal infection in women of childbearing age
- Signs and symptoms include:
 - Discharge – often creamy, white
 - Pain, burning, pruritus
 - Fishy odor
- Women who have never had intercourse are rarely affected
- Risk factors:
 - Multiple male or female partners, new partner, douching, lack of condom use

BACTERIAL VAGINOSIS IN HIV

- Associated with increased risk for HIV and other STIs
- Alteration in vaginal microbiome
- If not virally suppressed, also increases the risk of transmitting HIV to a partner during sex or to child during labor and delivery




BACTERIAL VAGINOSIS: DIAGNOSIS


- Changes in the vaginal environment can allow for an overgrowth of bacteria such as *Gardnerella vaginalis* *Mycoplasma hominis*, and other anaerobes
- CDC Diagnostic Criteria/Amsel's Criteria
 - 3 of the following:
 - Homogenous, thin, white discharge that coats vaginal walls
 - Clue cells (see next slide)
 - pH of vaginal fluid > 4.5
 - A fishy odor of vaginal discharge before or after addition of 10% KOH (whiff test)
- Gram stain is gold standard for BV diagnosis

BACTERIAL VAGINOSIS

Normal Vaginal Epithelial Cell



"Clue Cell"



See: http://depts.washington.edu/nnptc/online_training/std_handbook/gallery/pages/cluecells.html



CDC's Public Health Image Library, accessed October 15, 2020
<https://phil.cdc.gov/default.aspx>

Wet Mount Microscopy

BACTERIAL VAGINOSIS: TREATMENT


- Antibiotics
 - Metronidazole 500mg twice daily x 7 days, Metronidazole gel 0.75% 5g applicator intravaginally qday x 5 days, clindamycin (suppository), tinidazole
- Women with BV are at increased risk for STDs and HIV
 - All women with symptoms of BV should be treated to avoid complications
- BV also increases risk for HIV transmission to male partners
 - Male partners generally not treated
 - Men may serve as a reservoir of BV-associated bacteria, which could lead to recurrence and persistence
 - Penile anaerobes may play a role in HIV susceptibility in men

BACTERIAL VAGINOSIS: PREVENTION

- Condoms during sex
- Limit number of sex partners
- Do not douche
- Complete the entire course of antibiotics

TRICHOMONIASIS

- Affects 3.7 million people per year in US
- Increased cases in women > 40 years
 - Infection is associated with 2-3-fold increased risk for HIV, preterm birth, and adverse pregnancy outcomes in women of childbearing age
- Transmission between men who have sex with men is low
- Not thought to be transmitted through oral sex




TRICHOMONIASIS

- A parasitic disease that usually infects the vagina in women and the urethra in men
- Signs and symptoms include:
 - Men
 - Usually asymptomatic
 - Urethritis, epididymitis, prostatitis
 - Women may experience:
 - Thin discharge with odor
 - Irritation and itching

TRICHOMONIASIS: DIAGNOSIS

- Nucleic Acid Amplification Test (NAAT)
 - Highly sensitive in women, less so in men
 - Detects infection 3-5x more than with wet mount microscopy
- Culture
 - Former gold standard, NAAT is preferable
- Microscopic examination of vaginal or urethral fluid for parasites
 - Most common, low cost, but has lower sensitivity
- Rapid Tests
 - Only approved for use in women, vaginal secretions
 - Antigen detection, results in 10 minutes
 - DNA hybridization probe – Affirm VP III, results in 45 minutes

TRICHOMONIASIS



TRICHOMONIASIS: TREATMENT

- Metronidazole 2g orally in single dose OR tinidazole 2g in single dose
 - In person with HIV, treat with 500mg metronidazole twice daily x 7 days
- Alcohol should be avoided for at least 24 hours after taking treatment
 - Risk for disulfiram-like reaction
- Allergy to metronidazole
 - Desensitization


TRICHOMONIASIS: PREVENTION

- Condoms
- Limit number of sex partners
- Complete course of antibiotic treatment for all partners
 - Twenty percent of patients are re-infected within 3 months after treatment
 - Avoid sex until symptoms abate, usually about a week
 - Test of cure in 3 months for sexually active women
- Expedited Partner Therapy
 - April 2020 MDHHS Dear Colleague Letter
 - Secondary to COVID-19



CHLAMYDIA

- Most frequently reported STI in the United States, prevalence highest in persons <24 years.
- Can be transmitted during vaginal, oral, or anal sex
- Can be passed from mother to baby
- Signs and symptoms include:
 - Discharge
 - Burning on urination
 - Three quarters of women and half of men have no symptoms



CHLAMYDIA: COMPLICATIONS


- Can ascend the genital tract
- Can cause severe infection and sterility in men and women
 - Pelvic inflammatory disease, epididymitis, proctitis
- In pregnancy:
 - May lead to premature birth
 - Is the leading cause of newborn pneumonia and conjunctivitis
- Chlamydia and HIV
 - Role of inflammation and immune response to genital tract

CHLAMYDIA: DIAGNOSIS AND PREVENTION

- Diagnosis:
 - Nucleic Acid Amplification Tests (NAATs)
 - Vaginal swabs are preferred for females
 - First-catch urine is preferred for men, urethral swab acceptable
- Prevention:
 - Condoms during sex
 - Limit the number of sex partners
 - Get tested
 - Complete course of antibiotics for all partners



CHLAMYDIA



CHLAMYDIA: TREATMENT

- 1g azithromycin x 1 or doxycycline 100mg twice daily x 7 days
- Treat all partners
 - Re-infection is common
 - Expedited Partner Therapy is effective and approved in Michigan
 - Avoid sex for one week after initiating treatment
- Rectal chlamydia
 - Azithromycin 1gm x 1 if diagnosis made following asymptomatic screening
 - Doxycycline x 7 days if symptomatic rectal infection

CHLAMYDIA: LYMPHOGRANULOMA VENEREUM (LGV)

- Clinical Manifestations
 - Tender inguinal or femoral lymphadenopathy, typically unilateral
 - Self-limited genital ulcer at site of inoculation
 - Rectal exposure: proctocolitis, discharge (mucoid or hemorrhagic), anal pain, constipation, tenesmus
- Outbreaks have been observed among MSM in Michigan

LGV: DIAGNOSIS

Diagnosis

- Clinical suspicion
- Exclusion of other causes of proctocolitis, inguinal lymphadenopathy, and genital ulcers
- Diagnostic testing may not be readily available and test results often delayed
- Chlamydia NAAT on rectal specimen is recommended

LGV: TREATMENT

- Treatment based on clinical suspicion
- Treat presumptively based on symptom presentation while test results pending
 - Untreated infection may lead to systemic infection, chronic fistulas and strictures
- Doxycycline 100mg BID x 21 days
 - Alternative: erythromycin base 400mg 4 times a day for 21 days

The image shows the letters 'LGV' in a stylized, pink, hand-drawn font. The letters are thick and have a slightly irregular, textured appearance. They are set against a white background and are enclosed within a thin black rectangular border.

GONORRHEA

- Very common infectious disease
 - Prevalence is rising, 2nd most prevalent in US
 - Often co-occurs with chlamydia
- Spread through vaginal, oral, anal sexual contact
- Can spread to other mucous membranes
- Can be transmitted from mother to baby during deliver, causing:
 - Blindness
 - Sepsis
 - Joint infections



GONORRHEA AND HIV

- Role of inflammation in genital and rectal tissue
- Gonococcal urethritis increases the rate of HIV shedding
 - Increases transmission of HIV as well as increased rate of HIV acquisition
- Rates of gonorrhea are highest among young, black/African American men
 - Mirrors demographic at greatest risk for HIV and demographic with greatest burden of HIV infections


GONORRHEA: SIGNS AND SYMPTOMS

- Men are often symptomatic with:
 - Burning on urination
 - Yellow/green discharge from the penis
 - Pain and swelling in the testicles
- Women may be asymptomatic or may experience:
 - Symptoms which mimic bladder infection
 - Burning and yellow or bloody vaginal discharge

EXTRAGENITAL GONORRHEA

- Rectal infection:
 - Pain, itching, discharge, bleeding
- Pharyngeal infection:
 - Pain, swollen lymph nodes in the neck
- Eye infection:
 - Pain, sensitivity to light, and pus-like discharge from one or both eyes

GONORRHEA



GONORRHEA: DIAGNOSIS

- Diagnosis can be performed using:
 - Nucleic Acid Amplification Test (NAAT)
 - Culture from infected site
 - Urine culture
 - Gram stain
- Untreated gonorrhea can lead to severe infections, including sepsis, infertility, pelvic inflammatory disease, epididymitis

GONORRHEA: TREATMENT

- Infection of cervix, urethra or rectum:
 - Ceftriaxone 500mg IM in single in persons <150kg
 - Ceftriaxone 1g IM in single dose for persons >150kg
 - If chlamydia infection has not been excluded, treat for chlamydia with doxycycline 100mg PO BID x 7 days
- Treatment is complicated by the ability of gonorrhoea to develop resistance to antimicrobial therapies
- Re-infection is common
 - Treat all partners
 - Avoid sex for one week after initiating treatment
 - EPT available

GONORRHEA TREATMENT: PHARYNX

- Most infections are asymptomatic
- More difficult to eradicate than infections in genital and anorectal sites
- No reliable alternative treatments are available per CDC STD Guidelines
- For pharyngeal infection a test-of-cure (TOC) is recommended with either culture or NAAT 7-14 days after initial treatment

GONORRHEA: PREVENTION

- Condoms
- Frequent testing
- Limit the number of sex partners
- Complete course of treatment for all partners



Expedited
Partner Therapy

HERPES SIMPLEX VIRUS (HSV)

- Common in the United States
 - 776,000 people get new genital herpes simplex virus (HSV) infections annually
- 11.9% of persons 14-49 have HSV-2
 - Rate of genital HSV is higher because an increasing number are now caused by HSV-1
 - HSV-1 genital infections becoming more common in young women and men who have sex with men
- More common in women than men
 - More easily transmitted from men to women than from women to men during penile-vaginal sex
- Most are unaware of their infection
 - 87.4% of 14-49 year olds infected with HSV-2 have never received a clinical diagnosis


HSV AND PREGNANCY

- Pregnant women and women of childbearing age should notify healthcare providers of their infection
- Risk for transmission to neonate is higher if HSV acquired near delivery and lower if there is a prenatal history or acquired during first half of pregnancy
- Goal is prevention of HSV during late pregnancy and preventing exposure of neonate to lesions during delivery
- Routine HSV-2 serologic screening of pregnant women is not recommended
- Vaginal delivery okay if asymptomatic; cesarean delivery if lesions at onset of labor

HSV: DIAGNOSIS

- Laboratory confirmation of HSV is recommended for patients with clinical disease and their partners to guide counseling and management
 - PCR - Preferred testing method due to higher sensitivity
 - Viral culture - Low sensitivity, accuracy declines rapidly as lesions heal and is less accurate for recurrent lesions
 - Serologic type-specific assay
 - Risk for false negative results, lack of site specificity
 - HSV-2 almost always anogenital but the same cannot be said for HSV-1
 - May take 4 months for antibody development

HERPES SIMPLEX VIRUS



HERPES SIMPLEX VIRUS




HERPES SIMPLEX VIRUS: TREATMENT

- Systemic antiviral drugs can partially control the signs and symptoms of genital herpes
 - Three antiviral medications provide clinical benefit for genital herpes:
 - Acyclovir
 - Valacyclovir
 - Famciclovir
 - These drugs do not eradicate latent virus or affect the risk/frequency/severity of recurrences after the drug is discontinued
- All patients with initial outbreak should receive antivirals
- Suppressive therapy reduces the frequency of genital herpes recurrences by 70%–80% in patients who have frequent recurrences


HUMAN PAPILLOMA VIRUS (HPV)

- Most common STI in the United States
- More than 150 strains or types of HPV
 - 40 strains are sexually transmitted
- At least 75% of sexually active adults contract HPV in their lifetime
- Most persons who acquire HPV clear the infection spontaneously and have no associated health problems
 - Oncogenic (HPV types 16 and 18) cause most cancer of the cervix, anus, penis, oropharynx
 - Low risk HPV infections (HPV types 6 and 11) cause genital warts
- Can be transmitted from mother to baby during vaginal delivery
- Asymptomatic shedders carry high potential for spreading the virus



HUMAN PAPILLOMA VIRUS: SIGNS AND SYMPTOMS

- Can have no symptoms or can have soft, moist flesh-colored growths or bumps in genital area
- Diagnosis:
 - Inspection
 - Pap smear with high risk HPV DNA testing
 - Colposcopy/anoscopy
 - Acetic acid solution test
 - Biopsy
 - DNA test



HPV: DIAGNOSIS AND TREATMENT

- No HPV test can determine which HPV infection will clear and which will progress
- However, in certain circumstances, HPV tests can determine whether a woman is at increased risk for cervical cancer
 - These tests are not for detecting other HPV-related problems, and have less clinical utility in women aged <25 years or men of any age
- Treatment:
 - Usually goes away on its own
 - Cancer-related types are most likely to persist
 - Can be removed, but may reoccur
 - HPV-related cancers are more treatable when diagnosed and treated early

HUMAN PAPILLOMA VIRUS



HUMAN PAPILLOMA VIRUS



HUMAN PAPILLOMA VIRUS: PREVENTION

- Get vaccinated!
- Limit the number of sex partners
- Avoid sex with persons who have lesions in genital area
- Condoms may reduce risk
- Regular PAP tests

HUMAN PAPILOMA VIRUS: VACCINES

- Two doses of the HPV vaccine are recommended for all boys and girls at ages 11–12
 - Can be given as early as age 9
 - Catch up vaccine through age 26 if not previously vaccinated
- In October 2018, FDA approved an expansion of the age indication through age 45 years for Gardasil-9
 - CDC states: For adults aged 27 through 45 years, public health benefit of HPV vaccination in this age range is minimal; shared clinical decision-making is recommended because some persons who are not adequately vaccinated might benefit.


SYPHILIS

- Called the “great imitator” because its symptoms mimic other diseases
- Spread through direct contact with a syphilis lesion during oral, vaginal or anal sex
- Devastating consequences if left untreated
- Can facilitate transmission of HIV
- Rising rates in MSM, women, as well as congenital transmission



SYPHILIS: EPIDEMIOLOGY

- 115,045 reported new diagnoses of syphilis (all stages) in 2018
 - 35,063 were primary and secondary syphilis, which are the earliest and most transmissible stages of the infection
 - In 2018, the majority of primary and secondary syphilis cases occurred among gay, bisexual, and other men who have sex with men (MSM)




<https://www.cdc.gov/std/stats> Accessed October 15, 2020

<https://www.cdc.gov/std/statistics/2019/figures/SYPH-1.htm>

SYPHILIS: STAGES


- Syphilis is described in terms of its four stages:
 - Primary
 - Secondary
 - Latent (hidden)
 - Tertiary (late)



PRIMARY SYPHILIS

- Primary stage:
 - Time from infection to the presence of first symptom ranges from 10-90 days
 - Single lesion (chancre) appears on the body at the place where the bacterium entered
 - Chancre is small, firm, round, painless and lasts for 3-6 weeks
 - Multiple painful lesions are also possible

PRIMARY SYPHILIS IMAGES



PRIMARY SYPHILIS IMAGES




SECONDARY SYPHILIS

- Occurs weeks to months after initial chancre in 25% of patients
- Systemic symptoms often present such as rash, fever, myalgia, fatigue, adenopathy, headaches
- Rash
 - May appear anywhere on the body and is maculopapular, non-pruritic
 - Characteristic palmar/plantar distribution
 - On light skin may appear erythematous, on dark skin may appear as dark hyper-pigmented
- Can have patchy hair loss; moth-eaten appearance
- Condyloma lata, large, often moist, gray-white lesions, can appear in warm moist areas


SECONDARY SYPHILIS IMAGES



SECONDARY SYPHILIS IMAGES



SECONDARY SYPHILIS IMAGES




SECONDARY SYPHILIS IMAGES



TERTIARY SYPHILIS

- Develops in a subset of untreated syphilis infection
- It can occur 10-30 years after initial untreated infection and be fatal
- Can affect multiple organ systems, including the:
 - Brain
 - Nerves
 - Eyes
 - Heart
 - Blood vessels
 - Liver
 - Bones and joints
- Symptoms vary depending on the organ system affected

TERTIARY SYPHILIS IMAGES



LATENT SYPHILIS

- No external symptoms
- Early latent
 - Acquired within past 12 months
- Late latent
 - Infection occurred >12 months ago
 - Can last for years
- How to determine?

NEUROSYPHILIS

- Syphilis can invade the nervous system at any stage of infection, causing a wide range of symptoms, including:
 - Headache
 - Altered behavior
 - Difficulty coordinating muscle movements
 - Paralysis
 - Sensory deficits
 - Dementia

OCULAR SYPHILIS

- Syphilis can involve almost any eye structure
 - Posterior uveitis and pan uveitis are the most common
 - Symptoms include:
 - Vision changes
 - Decreased visual acuity
 - Permanent blindness
- Screen for eye complaints in any person at risk for syphilis or with known syphilis



CONGENITAL SYPHILIS

Morbidity and Mortality Weekly Report

Increase in Incidence of Congenital Syphilis — United States, 2012–2014


Virginia Bowen, PhD^{1,2}; John Su, MD, PhD³; Elizabeth Torrone, PhD²; Sarah Kidd, MD²; Hillard Weinstock, MD²

Pregnant women can pass syphilis to their babies who may:

- Die before or shortly after birth
- Become developmentally delayed
- Have seizures



CONGENITAL SYPHILIS




SYPHILIS: DIAGNOSIS

- Dark field microscopy from fluid from lesion
- Blood test
 - Non-treponemal test
 - VDRL, RPR
 - Measure IgM and IgG antibody and are not specific for *T. pallidum*
 - Correlate with disease activity, reported quantitatively
 - Usually become nonreactive with time with or without treatment
 - Treponemal test
 - TP-PA, FTA-ABS, EIA
 - Measure antibody directed against *T. pallidum*
 - Correlate poorly with disease activity
 - Often reactive for life

SYPHILIS SCREENING: ALGORITHM

Syphilis serologic screening algorithms

Traditional



Reverse sequence





Figure 4. Example of Quantitative Nontreponemal Titers That Indicate a Clinically-significant Change



SYPHILIS: TREATMENT

- Preferred treatment for all stages of syphilis is benzathine penicillin G
 - Primary, secondary and early latent syphilis (< 1 year)
 - 2.4 million units IM, once
 - Late latent syphilis (> 1 year)
 - 2.4 million units IM once every week for 3 weeks
 - Asymptomatic neurosyphilis, HIV negative
 - Aqueous crystalline penicillin G 18–24 million units per day, administered as 3–4 million units IV every 4 hours or continuous infusion, for 10–14 days
 - Procaine PCN-G at 2.4 million U/d intramuscularly plus probenecid at 500 mg orally 4 times per day for 10-14 days
- Pregnant women should be treated with the penicillin regimen appropriate for their stage of infection
 - If allergic to penicillin, should be referred for desensitization

SYPHILIS: PREVENTION

- Limit the number of sex partners
- Condoms during sex may reduce risk
- Complete course of antibiotic treatment
- Sex partners are considered at risk for infection and should be confidentially notified of exposure and need for evaluation/possible treatment
 - MDHHS Disease Intervention Specialist
 - https://www.michigan.gov/mdhhs/0,5885,7-339-71550_2955_2982-507318--,00.html

SYPHILIS AND HIV

- Syphilis poses an increased risk for transmission and acquisition of HIV
- Persons with HIV and syphilis are more likely to have severe syphilis symptoms, and experience stages of syphilis that are more likely to overlap
 - Numerous primary chancres and chancres that take longer to resolve
 - Secondary syphilis symptoms without having experienced a primary chancre
 - Higher risk of developing neurosyphilis, especially in individuals with low CD4+ T cell counts and high HIV viral load
 - Higher likelihood of slow serologic response following treatment and treatment failure
 - Also more likely to experience a serofast state, prolonged elevated non-treponemal titers for years after treatment

IMPORTANCE OF TAKING A ROUTINE SEXUAL HISTORY

- A sexual history needs to be taken during a patient's initial visit, during routine preventive exams, and whenever a patient presents with signs of sexually transmitted infection
 - A sexual history helps to identify an individual's risk for STIs, including HIV, and to identify appropriate anatomical sites for certain STI tests
- “5 P’s” is a tool that facilitates discussion with patients about:
 - Partners
 - Practices
 - Protection from STDs
 - Past history of STDs
 - Prevention of pregnancy

TAKING A SEXUAL HEALTH HISTORY: TOPICS/QUESTIONS

Preferences	What terms do you use to refer to your body?
Partners	Are you sexually active? How do your partners identify? What gender do they use/prefer?
Practices	Who puts what where? Are toys used
Protection	Are there some types of sex where you do not use barriers?
Past history of STDs	If yes, do you remember the site or type of STD?
Pregnancy	Do you have reproductive goals? Are you concerned about getting pregnant or getting your partner pregnant?
Pleasure	Are you able to become aroused with sexual activity? Any pain or discomfort?
Partner violence	Has anyone ever forced or compelled you to do something sexually that you did not want to do? (check in before doing PAP)

REFERENCES

- Centers for Disease Control and Prevention MMWR Vol 64, No. 3, *Sexually Transmitted Diseases Treatment Guidelines*, 2015.
- Michigan Department of Health and Human Services *EPT for Chlamydia and Gonorrhea Guidance for Healthcare Providers*
https://www.michigan.gov/documents/mdch/EPT_for_Chlamydia_and_Gonorrhea_-_Guidance_for_Health_Care_Providers_494241_7.pdf
- University of Washington National STD Curriculum – <https://www.std.uw.edu/>
- Michigan Department for Health and Human Services <https://www.michigan.gov/mdhhs>
- Centers for Disease Control www.CDC.gov

FOR MORE INFORMATION...

The screenshot shows the top navigation bar with icons for Self Study, Quick Reference, Question Bank, Clinical Consultation, Master Bibliography, and STD Podcast. Below this is the main header for the National STD Curriculum, including a description as a free educational website from the University of Washington STD Prevention Training Center, a Contributors link, and funding information from the CDC. A central illustration depicts the progression of an STD through a cell. Below the header is a section titled 'STD & STI Modules' containing a grid of six modules: Chlamydia, Gonorrhea, HSV (Herpes Simplex Virus - Genital), HPV (Human Papillomavirus Infection), PID (Pelvic Inflammatory Disease), and Syphilis. Each module card includes a representative image, the disease name, and three interactive options: Quick Reference, Self-Study (with CNE/CME credit), and Question Bank (with CNE/CME credit).

National STD Curriculum
A free educational website from the University of Washington STD Prevention Training Center.
Contributors
Funded by Centers for Disease Control and Prevention (CDC)

STD & STI Modules

 Chlamydia	Quick Reference > Rapidly access info about Chlamydia	Self-Study CNE/CME Track progress and receive CE credit	Question Bank CNE/CME Interactive board-review style questions with CE credit
 Gonorrhea	Quick Reference > Rapidly access info about Gonorrhea	Self-Study CNE/CME Track progress and receive CE credit	Question Bank CNE/CME Interactive board-review style questions with CE credit
 HSV Herpes Simplex Virus - Genital	Quick Reference > Rapidly access info about HSV	Self-Study CNE/CME Track progress and receive CE credit	Question Bank CNE/CME Interactive board-review style questions with CE credit
 HPV Human Papillomavirus Infection	Quick Reference > Rapidly access info about HPV	Self-Study CNE/CME Track progress and receive CE credit	
 PID Pelvic Inflammatory Disease	Quick Reference > Rapidly access info about PID	Self-Study CNE/CME Track progress and receive CE credit	
 Syphilis	Quick Reference > Rapidly access info about Syphilis	Self-Study CNE/CME Track progress and receive CE credit	Question Bank CNE/CME Interactive board-review style questions with CE credit

<https://www.std.uw.edu/>

Thank you!

Questions?

matecmichigan@gmail.com

Questions answered within 24 – 48 hours



WAYNE STATE
School of Medicine

AIDS Research and Education Center